the aethlon medical (nasdaq:aemd) mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. our aethlon adapt™ platform provides the technology foundation for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. the aethlon adapt™ product pipeline includes the hemopurifier®, a first-in-class medical device with broad-spectrum capabilities against exosomes that contribute to the progression of cancer and infectious viral pathogens such as hiv and hepatitis c.
Company profile
Ticker
AEMD
Exchange
Website
CEO
Timothy Rodell
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BISHOP EQUITIES INC
SEC CIK
Corporate docs
Subsidiaries
Owned by Aethlon Medical, Inc. • Aethlon Medical Australia Pty Ltd ...
IRS number
133632859
AEMD stock data
Latest filings (excl ownership)
10-Q
2024 Q3
Quarterly report
14 Feb 24
8-K
Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update
14 Feb 24
8-K/A
Departure of Directors or Certain Officers
22 Dec 23
8-K
Departure of Directors or Certain Officers
27 Nov 23
10-Q
2024 Q2
Quarterly report
14 Nov 23
8-K
Aethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate Update
14 Nov 23
8-K
Departure of Directors or Certain Officers
13 Nov 23
8-K
Aethlon Announces Reverse Stock Split
4 Oct 23
8-K
Submission of Matters to a Vote of Security Holders
18 Sep 23
10-Q
2023 Q1
Quarterly report
10 Aug 23
Transcripts
AEMD
Earnings call transcript
2024 Q3
14 Feb 24
AEMD
Earnings call transcript
2024 Q2
14 Nov 23
AEMD
Earnings call transcript
2024 Q1
10 Aug 23
AEMD
Earnings call transcript
2023 Q4
28 Jun 23
AEMD
Earnings call transcript
2023 Q3
13 Feb 23
AEMD
Earnings call transcript
2022 Q2
14 Nov 22
AEMD
Earnings call transcript
2023 Q1
10 Aug 22
AEMD
Earnings call transcript
2022 Q4
28 Jun 22
AEMD
Earnings call transcript
2022 Q3
15 Feb 22
AEMD
Earnings call transcript
2022 Q2
10 Nov 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 10.26 mm | 10.26 mm | 10.26 mm | 10.26 mm | 10.26 mm | 10.26 mm |
Cash burn (monthly) | 907.27 k | 785.68 k | 1.06 mm | 992.60 k | 901.38 k | 840.36 k |
Cash used (since last report) | 5.41 mm | 4.68 mm | 6.31 mm | 5.92 mm | 5.37 mm | 5.01 mm |
Cash remaining | 4.85 mm | 5.58 mm | 3.95 mm | 4.34 mm | 4.89 mm | 5.25 mm |
Runway (months of cash) | 5.3 | 7.1 | 3.7 | 4.4 | 5.4 | 6.3 |
Institutional ownership, Q2 2023
39.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 26 |
Opened positions | 3 |
Closed positions | 4 |
Increased positions | 2 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 251.29 mm |
Total shares | 1.03 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 198.15 k | $71.31 mm |
Intracoastal Capital | 179.12 k | $442.00 k |
Geode Capital Management | 169.43 k | $60.99 mm |
Iroquois Capital Management | 104.57 k | $258.00 k |
BLK Blackrock | 73.83 k | $26.57 mm |
Two Sigma Investments | 53.55 k | $19.27 mm |
Allegiance Financial Group Advisory Services | 50.00 k | $18.00 mm |
STT State Street | 36.30 k | $13.07 mm |
NTRS Northern Trust | 28.29 k | $10.18 mm |
Renaissance Technologies | 19.77 k | $7.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Dec 23 | Broenniman Edward G | Common Stock | Payment of exercise | Dispose F | No | No | 2.19 | 1,163 | 2.55 k | 13,733 |
29 Dec 23 | Shah Chetan | Common Stock | Payment of exercise | Dispose F | No | No | 2.19 | 1,163 | 2.55 k | 12,801 |
29 Dec 23 | Nicolas Gikakis | Common Stock | Payment of exercise | Dispose F | No | No | 2.19 | 1,954 | 4.28 k | 15,634 |
29 Sep 23 | Nicolas Gikakis | Common Stock | Payment of exercise | Dispose F | No | No | 0.23 | 19,541 | 4.49 k | 175,873 |
29 Sep 23 | Broenniman Edward G | Common Stock | Payment of exercise | Dispose F | No | No | 0.23 | 11,628 | 2.67 k | 148,957 |
News
HC Wainwright & Co. Maintains Buy on Aethlon Medical, Lowers Price Target to $10
4 Mar 24
Aethlon Medical Enters Into Materials Transfer Agreement For Santersus AG's NucleoCapture And HemoNucleoCapture Devices
21 Feb 24
Recap: Aethlon Medical Q3 Earnings
14 Feb 24
Aethlon Medical Q3 EPS $(1.37) Misses $(1.23) Estimate
14 Feb 24
Earnings Scheduled For February 14, 2024
14 Feb 24
Press releases
Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices
21 Feb 24
Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update
14 Feb 24
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024
7 Feb 24